
What a Prostate Nodule Detection Like Biden's Can Mean for a Man's Health
Former President Joesph Biden has what a spokesman described as a 'small nodule' in his prostate. How worried a patient should be by such a finding depends on the circumstances, urologists said.
In some cases, nodules are caused by inflammation, which can make the prostate feel firmer, or can lead to calcifications in the prostate that feel like nodules. These are benign.
They can also result from a common condition in older men, nodular benign prostatic hypertrophy, in which nonthreatening nodules form in the prostate, enlarging it. These also pose no risk.
But in the worst cases, they can be cancers.
When a urologist feels a nodule in a man's prostate, it is not always clear what to make of it, said Dr. Scott Eggener, a urologist at the University of Chicago.
'There absolutely are times when it is vague and equivocal and you don't know what it is,' he said, adding that a growth may feel like 'a big bulky rock that is almost certainly cancer.'
But, Dr. Eggener said, he wonders why a doctor was manually examining Mr. Biden's prostate in the first place. Perhaps he had a new symptom, like a urinary issue, or pain, or an elevated level of prostate-specific antigen, or PSA, a blood protein whose level rises with prostate cancer.
If the exam was just part of routine screening, it would be contrary to guidelines issued by professional organizations that argue against prostate screening for men Mr. Biden's age, unless they are in unusually good health.
That is because prostate cancers tend to grow slowly, if at all, and are very common in men Mr. Biden's age, Dr. Eggener said.
'At least 50 percent of men his age have cancer in their prostate,' Dr. Eggener said. 'The overwhelming majority are better off not knowing about it.' They may die with the slow-growing cancer, not of it. They may have no symptoms and it may not threaten their lives.
Screening for a man Mr. Biden's age is 'very controversial,' said Dr. Judd Moul, a urologist at Duke University.
He's been screened, though, so 'I guess at this point it's water under the bridge,' Dr. Moul said. 'Someone did a digital rectal exam and found something they deemed as abnormal.'
Now the issue will be how to evaluate the finding.
One usual method would be to do a PSA test. Alternatively, he could have a new urine test that looks for genetic signals of cancer.
Doctors could examine Mr. Biden's prostate with an MRI, or ultrasound.
'Ultimately, if they think this nodule is prostate cancer, the final step would be a biopsy,' Dr. Moul said.
And then, if it is cancer, Mr. Biden would face the difficult decision of whether or not to have it treated, which might require surgery or radiation.
'Sometimes when we are faced with older gentlemen with prostate nodules and other health issues, it can be appropriate just to monitor it,' Dr. Moul said.
Dr. Moul said that before he went down the path of further testing, he would first have a long talk with a patient like Mr. Biden about what that might lead to. If a patient finds out he has prostate cancer, he has to decide whether to undergo the treatment, which can be difficult, or live with the knowledge that he has cancer and that he is choosing not to treat it.
'I would try to make a shared decision with him before moving on to any further testing,' Dr. Moul said.
Mr. Biden's spokesman said he had spent Friday at a Philadelphia hospital and was undergoing additional evaluation.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
23 minutes ago
- Medscape
Fast Five Quiz: Opioid Use Disorder
Opioid use disorder (OUD) currently impacts approximately 16 million people worldwide. It is considered a significant public health issue, with experts noting a 'burden that is increasing' globally. As research into optimal management of OUD evolves, updates to clinical guidelines emphasize a more individualized approach to pharmacologic treatment, psychosocial support, and special considerations for specific patient populations, such as pregnant individuals. However, OUD remains a complex disease that comes with many serious health and legal concerns for both patients and clinicians. What do you know about OUD? Check your knowledge with this quick quiz. Despite pharmacologic treatment being known to be highly effective for treating OUD, a CDC report states that 30% of patients with OUD who require OUD treatment received only nonpharmacologic treatment. Further, 43% of patients did not perceive a need for OUD treatment at all. In this significant report, males aged 35-49 years were most likely to receive OUD treatment with medications, while females and younger and older adults had lower rates of access to pharmacologic interventions. The CDC concluded that engaging patients needing OUD treatment with pharmacologic interventions is 'essential.' Learn more about essential statistics for OUD. Data from a predictive-model study indicate that service setting was the strongest predictor for premature discontinuation of OUD treatment. The strength of this predictor declined with length of stay, becoming negligent after 365 days. Other system-level factors such as geographic region, primary source of payment for treatment, and referral source were also strong predictors of early discontinuation; individual factors such as age of first use, sex, and race were less predictive. Previous research cited by the study has also stressed the importance of reducing system-level barriers to care, and the updated federal guidance for opioid treatment programs have expanded access in several ways. Learn more about OUD guidance. Precipitated withdrawal can occur when transferring a patient from methadone to buprenorphine due to buprenorphine being only a partial opioid agonist; as such, the traditional method of transfer involves putting the patient in a controlled, moderate withdrawal state before initiating buprenorphine therapy. However, a novel dosing strategy called microinduction, which involves starting buprenorphine at submilligram doses (or 'low-dose induction'), and cross-tapering with methadone can prevent precipitated withdrawal. Additionally, this method is ideal for patients who want to switch from methadone to buprenorphine and those with chronic use of intravenous or intranasal fentanyl. A recent systematic review found that microinduction and traditional transfer methods had similar rates of successful induction of buprenorphine at 95.6%. Learn more about safe withdrawal practices for OUD. Both the CDC and the latest American Society of Addiction Medicine (ASAM) guidelines specifically state that pharmacotherapy for OUD should be offered as early as possible in pregnancy to prevent harms to both the patient and the fetus, noting that pharmacotherapy for OUD has been associated with improved maternal outcomes. ASAM specifically states, 'increasing the dose or split dosing is often required, especially in the third trimester.' Federal guidelines emphasize that pregnant individuals seeking treatment for OUD are considered a priority for enrollment in opioid treatment programs. Once receiving treatment, they do not generally recommended medically supervised withdrawal from pharmacotherapy for pregnant patients as it might harm the fetus and patient; further, ASAM guidelines state that patients who undergo medically supervised withdrawal are at an increased risk for 'return to opioid use.' However, if a patient decides to proceed with medically supervised withdrawal, ASAM guidelines suggest physicians provide education and resources regarding associated risks. The CDC also specifically recommends against abruptly discontinuing opioids during pregnancy, citing data and resources from the American College of Obstetricians and Gynecologists and the Substance Abuse and Mental Health Services Administration. Learn more about OUD. Federal guidelines specify that opioid treatment programs must conduct at least eight random drug tests per year on their patients. These tests must use FDA approved products that test for commonly abused substances that might affect patient safety, recovery, or adherence to OUD treatment. ASAM affirms this requirement, noting that many patients might need more frequent testing and that eight tests per year 'should be viewed as a minimum.' Learn more about drug testing in OUD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.


Washington Post
43 minutes ago
- Washington Post
WTA to provide ranking protection for players pursuing fertility treatments
In a move described as 'groundbreaking,' the WTA announced Wednesday it will provide rankings protection to players who take a break from the tour to undergo fertility procedures such as egg or embryo freezing. 'Having the protected ranking there, so that players don't feel forced to come back early and risk their health again,' 2017 U.S. Open champion Sloane Stephens said to the BBC Wednesday, 'is the best thing possible.'

E&E News
an hour ago
- E&E News
Cancer patient urges SCOTUS not to dismiss Roundup verdicts
A Missouri man who developed non-Hodgkin lymphoma after using a popular weedkiller for decades wants the Supreme Court to reject the manufacturer's request to grant it immunity from his lawsuit and thousands of others. John Durnell in a brief filed Monday says a jury found that Monsanto's Roundup caused his blood cancer and that the company is liable for damages. But, he added, the company is arguing 'as it has argued with little success for years' that it should be immune from lawsuits that it says are barred by federal law. His filing comes after Bayer in April asked the high court to determine whether the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) should invalidate thousands of lawsuits that claim the company has a duty to warn about health risks from the product. Advertisement Bayer acquired Monsanto in 2018, and the company has been inundated with what it says were 'unfounded' legal challenges across the country from customers alleging the weedkiller was responsible for their cancers.